EKF Diagnostics highlighting cancer molecular diagnostics products at ASCO 2015

EKF Diagnostics will be exhibiting its range of molecular diagnostics products supporting personalized medicine in cancer at the 2015 American Society of Clinical Oncology (ASCO) annual meeting, 29th May to 2nd June, McCormick Place, Chicago, Illinois. Here 30,000 oncology professionals from around the world will be brought together to discuss the very latest in treatment modalities, therapies and research in the field, in order to apply this knowledge to enhance cancer patient care.

EKF subsidiary, Selah Genomics’ newly introduced PrecisionPath™ next generation sequencing (NGS) technology cancer test will be a key focus on Booth #19141. This first commercially available NGS panel molecular test priced under US$1000, which was recently launched in partnership with Greenville Health systems (GHS), paves the way for accessible, low-cost personalized medicine in colon cancer. At ASCO, key personnel from Selah Genomics will be on hand to discuss how PrecisionPath™ can help oncologists select the most effective treatment options for a patient based on the specific molecular profile of their tumor.

Also to be exhibited on the EKF booth, will be EKF Molecular Diagnostics’ PointMan™ DNA enrichment kits for the ultra-low level detection of cancer gene mutations in both tissue and blood biopsies. These include kits for enrichment of cancer biomarkers, such as KRAS, BRAF, EGFR, JAK2 and ESR1. Notably, data has recently been presented which identifies PointMan™ technology as an easy and useful method for non-invasively determining plasma EGFR T790M mutation status in late stage lung cancer patients.

Reference:

Nishikawa, S. et al. Non-invasive analysis for T790M mutations of EGFR using a selective amplification method. American Association for Cancer Research (AACR) Annual Meeting 2015.

Source: EKF Diagnostics

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    EKF Diagnostics. (2021, February 18). EKF Diagnostics highlighting cancer molecular diagnostics products at ASCO 2015. News-Medical. Retrieved on November 08, 2024 from https://www.news-medical.net/news/20150528/EKF-Diagnostics-highlighting-cancer-molecular-diagnostics-products-at-ASCO-2015.aspx.

  • MLA

    EKF Diagnostics. "EKF Diagnostics highlighting cancer molecular diagnostics products at ASCO 2015". News-Medical. 08 November 2024. <https://www.news-medical.net/news/20150528/EKF-Diagnostics-highlighting-cancer-molecular-diagnostics-products-at-ASCO-2015.aspx>.

  • Chicago

    EKF Diagnostics. "EKF Diagnostics highlighting cancer molecular diagnostics products at ASCO 2015". News-Medical. https://www.news-medical.net/news/20150528/EKF-Diagnostics-highlighting-cancer-molecular-diagnostics-products-at-ASCO-2015.aspx. (accessed November 08, 2024).

  • Harvard

    EKF Diagnostics. 2021. EKF Diagnostics highlighting cancer molecular diagnostics products at ASCO 2015. News-Medical, viewed 08 November 2024, https://www.news-medical.net/news/20150528/EKF-Diagnostics-highlighting-cancer-molecular-diagnostics-products-at-ASCO-2015.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
EKF Diagnostics acquires ADL Health molecular diagnostic testing laboratory